Glaxo's HIV launches continue to shine; U.K. cost watchdog slaps conditions on BMS hep C treatment;

> New GlaxoSmithKline ($GSK) launches--including HIV drugs Tivicay and Triumeq--helped the company offset sliding sales of Advair/Seretide in Q2, it said. Video

> The U.K.'s cost watchdog has restricted use of Bristol-Myers Squibb ($BMY) hep C treatment Daklinza to patients with genotype 1 or 4 who have either had previous drug treatment or who can't receive interferon. Report

> Pfizer's ($PFE) new cancer fighter Ibrance now boasts 22% market share among patients with estrogen-receptor-positive, HER2-negative tumors--up from 10% last quarter, CEO Ian Read said Tuesday. More

> Marina Maher Communications has hired Matthew Anderson as EVP and CMO as its pharmaceutical business continues to expand. Report

And Finally... Fat cartoon characters may make children eat more, a new study says. More

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.

Bristol-Myers Squibb and Pfizer's Eliqus has taken the U.S. warfarin alternative market by storm, but can afib screening amp it up even more?